The pathophysiology and management of acute traumatic coagulopathy

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 7, 2015, Pages 645-652

  Duan, Kaipeng ^a   Yu, Wenkui ^a   Li, Ning ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

coagulopathy; mechanism; trauma; treatment

Indexed keywords

BLOOD CLOTTING FACTOR; CATECHOLAMINE; FIBRINOGEN; FRESH FROZEN PLASMA; PROTEIN C; RECOMBINANT ACTIVATED FACTOR VII; RECOMBINANT PROTEIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ACIDOSIS; ACUTE DISEASE; ACUTE TRAUMATIC COAGULOPATHY; ARTICLE; BLOOD CLOTTING DISORDER; DILUTION; ENZYME ACTIVATION; FIBRINOLYSIS; GLYCOCALYX; HUMAN; HYPOTHERMIA; INFLAMMATION; META ANALYSIS; PATHOPHYSIOLOGY; PERFUSION; PLASMA TRANSFUSION; PLATELET SUPPLEMENT; PRIORITY JOURNAL; RESUSCITATION; SUPPLEMENTATION; SYSTEMATIC REVIEW; THROMBOCYTE DYSFUNCTION; ANIMAL; BLOOD; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; MALE; METABOLISM; VASCULAR ENDOTHELIUM; WOUNDS AND INJURIES;

ACUTE DISEASE; ANIMALS; CATECHOLAMINES; DISSEMINATED INTRAVASCULAR COAGULATION; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; GLYCOCALYX; HUMANS; MALE; PROTEIN C; WOUNDS AND INJURIES;

EID: 84940878085     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613516190     Document Type: Article

References (84)

1. Maegele M, Lefering R, Yucel N,. Early coagulopathy in multiple injury: an analysis from the German trauma registry on 8724 patients. Injury. 2007; 38 (3): 298-304.
2. Krug EG, Sharma GK, Lozano R,. The global burden of injuries. Am J Public Health. 2000; 90 (4): 523-526.
3. Sauaia A, Moore FA, Moore EE,. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995; 38 (2): 185-193.
4. Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC,. Early predictors of postinjury multiple organ failure. Arch Surg. 1994; 129 (1): 39-45.
5. Hess JR, Brohi K, Dutton RP,. The coagulopathy of trauma: a review of mechanisms. J Trauma. 2008; 65 (4): 748-754.
6. Frith D, Goslings JC, Gaarder C,. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost. 2010; 8 (9): 1919-1925.
7. Davenport R, Manson J, De'Ath H,. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med. 2011; 39 (12): 2652-2658.
8. Brohi K, Singh J, Heron M, Coats T,. Acute traumatic coagulopathy. J Trauma. 2003; 54 (6): 1127-1130.
9. Floccard B, Rugeri L, Faure A,. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury. 2012; 43 (1): 26-32.
10. Brohi K, Cohen MJ, Davenport RA,. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007; 13 (6): 680-685.
11. Davenport R,. Pathogenesis of acute traumatic coagulopathy. Transfusion. 2013; 53 suppl 1: 23S-27S.
12. Gando S,. Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. you are now going down the wrong path. J Trauma. 2009; 67 (2): 381-383.
13. Paul TE, J Damian PG, Sandy LW,. Widder trauma-related coagulopathy-current concepts. Oncol Hematol Rev. 2012; 8 (2): 123-128.
14. Gando S, Wada H, Kim HK,. Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock. J Thromb Haemost. 2012; 10 (12): 2593-2595.
15. Gando S, Wada H, Thachil J, Scientific, Standardization Committee on DICotISoT, Haemostasis. Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost. 2013; 11 (5): 826-835.
16. Yanagida Y, Gando S, Sawamura A,. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery. 2013; 154 (1): 48-57.
17. Johansson PI, Sorensen AM, Perner A,. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? an observational study. Crit Care. 2011; 15 (6): R272.
18. Rizoli S, Nascimento B Jr, Key N,. Disseminated intravascular coagulopathy in the first 24 hours after trauma: the association between ISTH score and anatomopathologic evidence. J Trauma. 2011; 71 (5 suppl 1): S441-S447.
19. Johansson PI, Stissing T, Bochsen L, Ostrowski SR,. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med. 2009; 17: 45.
20. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF,. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007; 245 (5): 812-818.
21. Cohen MJ, Call M, Nelson M,. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg. 2012; 255 (2): 379-385.
22. Chesebro BB, Rahn P, Carles M,. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock. 2009; 32 (6): 659-665.
23. Esmon CT, Ding W, Yasuhiro K,. The protein C pathway: new insights. Thromb Haemost. 1997; 78 (1): 70-74.
24. Levi M, van der Poll T,. Inflammation and coagulation. Crit Care Med. 2010; 38 (2 suppl): S26-S34.
25. Aird WC,. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101 (10): 3765-3777.
26. Pries AR, Secomb TW, Gaehtgens P,. The endothelial surface layer. Pflugers Arch. 2000; 440 (5): 653-666.
27. Rehm M, Zahler S, Lotsch M,. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology. 2004; 100 (5): 1211-1123.
28. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES,. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005; 16 (5): 507-511.
29. Kozar RA, Peng Z, Zhang R,. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg. 2011; 112 (6): 1289-1295.
30. Rehm M, Bruegger D, Christ F,. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007; 116 (17): 1896-1906.
31. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR,. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011; 254 (2): 194-200.
32. Ostrowski SR, Johansson PI,. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg. 2012; 73 (1): 60-66.
33. Johansson PI, Ostrowski SR,. Acute coagulopathy of trauma: balancing progressive catecholamine induced endothelial activation and damage by fluid phase anticoagulation. Med Hypotheses. 2010; 75 (6): 564-567.
34. von Kanel R, Dimsdale JE,. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol. 2000; 65 (6): 357-369.
35. Brohi K, Cohen MJ, Ganter MT,. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008; 64 (5): 1211-1217.
36. Martini WZ, Chinkes DL, Sondeen J, Dubick MA,. Effects of hemorrhage and lactated Ringer's resuscitation on coagulation and fibrinogen metabolism in swine. Shock. 2006; 26 (4): 396-401.
37. Martini WZ, Chinkes DL, Pusateri AE,. Acute changes in fibrinogen metabolism and coagulation after hemorrhage in pigs. Am J Physiol Endocrinol Metab. 2005; 289 (5): E930-E934.
38. Martini WZ,. The effects of hypothermia on fibrinogen metabolism and coagulation function in swine. Metabolism. 2007; 56 (2): 214-221.
39. Martini WZ,. Fibrinogen metabolic responses to trauma. Scand J Trauma Resusc Emerg Med. 2009; 17: 2.
40. Raza I, Davenport R, Rourke C,. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013; 11 (2): 307-314.
41. Bajzar L, Nesheim ME, Tracy PB,. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996; 88 (6): 2093-100.
42. Bajzar L, Jain N, Wang P, Walker JB,. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med. 2004; 32 (5 suppl): S320-S324.
43. Ohlin AK, Larsson K, Hansson M,. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost. 2005; 3 (5): 976-982.
44. Sawamura A, Hayakawa M, Gando S,. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res. 2009; 124 (5): 608-613.
45. Gando S,. Disseminated intravascular coagulation in trauma patients. Semi Throm Hemost. 2001; 27 (06): 585-592.
46. Gando S, Sawamura A, Hayakawa M,. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg. 2011; 254 (1): 10-19.
47. Hoffman M,. Remodeling the blood coagulation cascade. J Thromb Thrombolysis. 2003; 16 (1-2): 17-20.
48. Ruseva Adelaida L., Dimitrova AA,. A new understanding of the coagulation process-the cell-based model. J Biomed Clin Res. 2011; 4 (1): 17-22.
49. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR,. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999; 103 (6): 879-887.
50. Adam F, Verbeuren TJ, Fauchere JL, Guillin MC, Jandrot-Perrus M,. Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP. J Throm Haemost. 2003; 1 (4): 798-804.
51. Kutcher ME, Redick BJ, McCreery RC,. Characterization of platelet dysfunction after trauma. Journal Trauma Acute Care Surg. 2012; 73 (1): 13-19.
52. Levy JH,. Antifibrinolytic therapy: new data and new concepts. Lancet. 2010; 376 (9734): 3-4.
53. Esmon CT,. The interactions between inflammation and coagulation. Br J Haematol. 2005; 131 (4): 417-430.
54. Esmon CT,. Inflammation and thrombosis. J Thromb Haemost. 2003; 1 (7): 1343-1348.
55. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR,. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock. 2006; 26 (5): 430-437.
56. Glaros T, Larsen M, Li L,. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci (Landmark Ed). 2009; 14: 3988-3993.
57. Farkash U, Lynn M, Scope A,. Does prehospital fluid administration impact core body temperature and coagulation functions in combat casualties? Injury. 2002; 33 (2): 103-110.
58. Martini WZ,. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma. 2009; 67 (1): 202-208.
59. Martini WZ, Pusateri AE, Uscilowicz JM, Delgado AV, Holcomb JB,. Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma. 2005; 58 (5): 1002-1009.
60. D'Angelo MR, Dutton RP,. Management of trauma-induced coagulopathy: trends and practices. AANA J. 2010; 78 (1): 35-40.
61. Shaz BH, Winkler AM, James AB, Hillyer CD, MacLeod JB,. Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion. J Trauma. 2011; 70 (6): 1401-1407.
62. Holcomb JB,. Damage control resuscitation. J Trauma. 2007; 62 (6 suppl): S36-S37.
63. Holcomb JB, Jenkins D, Rhee P,. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007; 62 (2): 307-310.
64. Doran CM, Doran CA, Woolley T,. Targeted resuscitation improves coagulation and outcome. J Trauma Acute Care Surg. 2012; 72 (4): 835-843.
65. Davenport R, Khan S,. Management of major trauma haemorrhage: treatment priorities and controversies. Br J Haematol. 2011; 155 (5): 537-548.
66. Stanworth SJ, Hyde CJ, Murphy MF,. Evidence for indications of fresh frozen plasma. Transfus Clin Biol. 2007; 14 (6): 551-556.
67. Frith D, Davenport R, Brohi K,. Acute traumatic coagulopathy. Curr Opin Anaesthesiol. 2012; 25 (2): 229-234.
68. Rourke C, Curry N, Khan S,. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012; 10 (7): 1342-1351.
69. Grottke O, Braunschweig T, Henzler D, Coburn M, Tolba R, Rossaint R,. Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care. 2010; 14 (2): R62.
70. Stinger HK, Spinella PC, Perkins JG,. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008; 64 (2 suppl): S79-S85.
71. Schochl H, Frietsch T, Pavelka M, Jambor C,. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67 (1): 125-131.
72. Schochl H, Nienaber U, Hofer G,. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010; 14 (2): R55.
73. Aledort LM,. Off-label use of recombinant activated factor VII - safe or not safe? N Engl J Med. 2010; 363 (19): 1853-1854.
74. Stanworth SJ, Birchall J, Doree CJ, Hyde C,. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Datab Syst Rev. 2007;(2): CD005011.
75. Boffard KD, Riou B, Warren B,. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005; 59 (1): 8-15.
76. Hauser CJ, Boffard K, Dutton R,. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010; 69 (3): 489-500.
77. Levi M, Levy JH, Andersen HF, Truloff D,. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010; 363 (19): 1791-1800.
78. Pidcoke HF, Aden JK, Mora AG,. Ten-year analysis of transfusion in operation iraqi freedom and operation enduring freedom: increased plasma and platelet use correlates with improved survival. J Trauma Acute Care Surg. 2012; 73 (6 suppl 5): S445-S452.
79. Henry DA, Carless PA, Moxey AJ,. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007;(4): CD001886.
80. collaborators C-t. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376 (9734): 23-32.
81. collaborators C-, Roberts I, Shakur H,. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377 (9771): 1096-101,. 101 e1-e2.
82. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ,. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg. 2012; 147 (2): 113-119.
83. Godier A, Roberts I, Hunt BJ,. Tranexamic acid: less bleeding and less thrombosis? Crit Care. 2012; 16 (3): 135.
84. Jimenez JJ, Iribarren JL, Lorente L,. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care. 2007; 11 (6): R117.